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Recurrent De Novo NAHR Reciprocal Duplications in the
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Recent studies have identified both recessive and dominant forms of mitochondrial disease that result from ATAD3A variants. The reces-
sive form includes subjects with biallelic deletions mediated by non-allelic homologous recombination. We report five unrelated neo-
nates with a lethal metabolic disorder characterized by cardiomyopathy, corneal opacities, encephalopathy, hypotonia, and seizures
in whom amonoallelic reciprocal duplication at the ATAD3 locus was identified. Analysis of the breakpoint junction fragment indicated
that these 67 kb heterozygous duplications were likely mediated by non-allelic homologous recombination at regions of high sequence
identity in ATAD3A exon 11 and ATAD3C exon 7. At the recombinant junction, the duplication allele produces a fusion gene derived
from ATAD3A and ATAD3C, the protein product of which lacks key functional residues. Analysis of fibroblasts derived from two affected
individuals shows that the fusion gene product is expressed and stable. These cells display perturbed cholesterol andmitochondrial DNA
organization similar to that observed for individuals with severe ATAD3A deficiency. We hypothesize that the fusion protein acts
through a dominant-negative mechanism to cause this fatal mitochondrial disorder. Our data delineate a molecular diagnosis for this
disorder, extend the clinical spectrum associated with structural variation at the ATAD3 locus, and identify a third mutational mecha-
nism for ATAD3 gene cluster variants. These results further affirm structural variant mutagenesis mechanisms in sporadic disease traits,
emphasize the importance of copy number analysis in molecular genomic diagnosis, and highlight some of the challenges of detecting
and interpreting clinically relevant rare gene rearrangements from next-generation sequencing data.Since its initial association with a neurological disorder,1 it
has become apparent that disruption of the ATAD3 cluster,
and more specifically ATAD3A (MIM: 612316), is a signifi-
cant cause of pediatric disease. Variants at this locus are
associated with a wide phenotypic spectrum, including
pontocerebellar hypoplasia,2 hereditary spastic para-
plegia,3 and a syndromic neurological disorder character-
ized by peripheral neuropathy, hypotonia, cardiomyopa-
thy, optic atrophy, cerebellar atrophy, and seizures:1
Harel-Yoon syndrome (HAYOS [MIM: 617183]). The
different phenotypes can be attributed to a spectrum of
disease-causing variants that includes bi-allelic hypomor-
phic variants, bi-allelic deletions, and monoallelic domi-
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tified in five unrelated neonates with shared phenotypes
including corneal clouding, cardiomyopathy, hypotonia,
and white matter changes, thus expanding the genotype
spectrum of ATAD3-related disorders.
The ATAD3 cluster is composed of three paralogs with
extensive sequence homology, formed through tandem
segmental duplication: ATAD3A, ATAD3B (MIM:
612317), and ATAD3C (MIM: 617227). ATAD3A and
ATAD3B are protein-coding genes of near identical
sequence, differing primarily due to a stop-loss mutation
in ATAD3B that extends the protein by 62 amino acids;
ATAD3C is not known to be expressed. ATAD3A is a trans-
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Table 1. Clinical Features of Individuals with Duplication in ATAD3 Gene Cluster
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5
Sex male female male female male
Gestation term 38 weeks term 33þ3 weeks term
Apgars at birth 3 poor 1 5,8,9 1,0
Chronological
age at death
3 days 6 weeks 5 days 6 weeks 4 weeks
Cardiomyopathy HCM DCM DCM;
cardiomegaly
HCM;
cardiomegaly
HCM;
cardiomegaly
Congenital
cataracts
U ND ND ND ND
Corneal
opacity
U U U U U
Postnatal
hypotonia
U U U U U
Abnormality
of the external
genitalia
cryptorchidism and
micropenis
ND ND ND hypospadias
Seizures U diffuse abnormalities
on EEG
ND diffuse abnormalities
on EEG
U
Encephalopathy U ND U ND ND
Brain findings ND white matter changes;
simplified gyral
patterning; cerebellar
atrophy (MRI)
widespread
hypoxic brain
damage (post-
mortem)
diffuse bilateral
abnormal subcortical,
periventricular, and
deep white matter;
abnormal MR
spectroscopy
white matter changes,
generalized reduction
of brain volume (MRI);
abnormal MR spectroscopy
(lactate peak) on day 9
Contractures/
fetal akinesia
fetal akinesia ND contractures ND contractures
Edema/fetal
hydrops
ND fetal hydrops; edema fetal hydrops ND ND
Metabolic
investigations
increased excretion of
fumarate, malate,
2-ketoglutarate,
3-methylglutaconate,
and 3-methylglutarate
lactic acidosis ND lactic acidosis;
increased excretion
of 2OH butyrate,
fumarate, and 3OH
isobutyrate
lactic acidosis, increased
excretion of fumarate,
malate on day 22
Prior genetic
investigations
ArrayCGH; Prader-
Willi; SMA
prenatal
aneuploidy
ND arrayCGH; 202 gene
mitochondrial panel
arrayCGH, 27 gene
glycogen storage
disease panel
HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy; SMA, spinal muscular atrophy; ND, not detected.a fraction of which is found at contact sites between the in-
ner and outer mitochondrial membranes5 in complex with
TSPO, CYP11A1, and OPA1.6 ATAD3 has also been
shown to interact with mitochondrial nucleoprotein com-
plexes and to play roles in mtDNA organization and repli-
cation.2,7,8 More recently it has been shown to interact
with Drp1/DNM1L to support Drp1-induced mitochon-
drial division,9 a process that drives mtDNA segrega-
tion.10,11 Concordantly, ATAD3 dysfunction and defi-
ciency have a wide range of effects on mitochondrial
structure and function, characterized by disturbed mito-
chondrial morphology and fission dynamics,3,6 loss of
cristae,12 perturbed mtDNA and cholesterol metabolism,
impaired mitochondrial steroidogenesis,2,13 and decreased
levels of some mitochondrial oxidative phosphorylation
(OXPHOS) components.12 It is not clear whether the
disruption to the innermitochondrial membrane, mtDNA,The Americaand OXPHOS complexes are due directly to the absence of
ATAD34,12 or whether they are consequences of changes to
membrane architecture resulting from an altered choles-
terol content2,13 or a combination of the two.
We report de novo ATAD3 duplications identified in five
unrelated neonates through exome sequencing. Clinical
exome sequencing failed to identify any alternative mo-
lecular diagnosis potentially causative of the phenotype,
which is characterized by seizures (four of the five neo-
nates) and fetal akinesia and contractures (in three case
subjects). A clinical summary is shown in Table 1 and
clinical case reports are detailed in the Supplemental
Note. Informed consent was obtained and all processes
adhered to local and national ethical standards. The
duplication in the ATAD3 cluster was also detected by
arrayCGH for those subjects studied (subjects four and
five). The duplication is predicted to be the product ofn Journal of Human Genetics 106, 272–279, February 6, 2020 273
Figure 1. NAHR between ATAD3C Exon 8
and ATAD3A Exon 11 Produces a Fusion
Gene, with Variants at Key Functional Resi-
dues within the ATPase Domain
Gene intron-exon structures are shown in
cartoon format; open boxes indicate UTRs
while closed boxes indicate coding regions.
Arrows following the gene name indicate
reading direction, and the first exon is
labeled. Genes are shown in their relative
position on chromosome 1 in a 50 to 30 direc-
tion from left to right.
(A) Nucleotide sequence identity between
ATAD3A (chr1:1512151–1534687:1) and
ATAD3C (chr1:1449689–1470158:1) in a
sliding 500 bp window. ATAD3A and
ATAD3C exon positions are represented
below according to their relative position
within the KAlign alignment; this includes
alignment gaps. The 398 bp region of
100% sequence identity is marked in yellow.
(B) Reference arrangement of the ATAD3
cluster showing the exon structures of
ATAD3C (purple), ATAD3B (orange), and
ATAD3A (green). The duplicated region is
highlighted in red.
(C) The reference arrangement of the ATAD3 cluster above the predicted configuration following duplication.
(D) The exon structure of the ATAD3A-C fusion gene, with exons 1–11 derived from ATAD3A (green) and exons 12–16 derived from
ATAD3C (purple). The ATPase domain is underlined (Asn347-Leu475; PFam PF00004), with the position of a key functional residue,
Arg466, indicated by an arrow.
(E) Amino acid sequence of the ATPase domain of ATAD3A (top) and the predicted amino acids sequence of the ATAD3A-C fusion pro-
tein (bottom). The green residues are derived from ATAD3A, while the purple residues are derived from ATAD3C. A vertical bar (|) indi-
cates an identical amino acid, a colon (:) indicates a strongly conservative amino acid change (score > 0.5 in PAM250 matrix), and a
period (.) indicates a weakly conservative amino acid change (score ¼ < 0.5 in PAM250 matrix). The sequences differ at seven positions.non-alleleic homologous recombination (NAHR) be-
tween regions of high sequence homology in ATAD3C
and ATAD3A (Figure 1A) and encompasses ATAD3C
exons 8–12, ATAD3B, and ATAD3A exons 1–11 (Figures
1B, S1, and S2).
PCR and Sanger sequencing confirmed the presence of
the duplications, which showed a 1.2 kb proband-specific
amplicon (1.6 kb for subject four due to alternative primer
design; data not shown). No PCR product was amplified in
DNA derived from unaffected parents, consistent with a
de novo event, and proband-parent relationships were
confirmed for all case subjects during exome analysis.
The 50 end of the PCR amplicon was derived from ATAD3A
exon 10, while the 30 was derived from ATAD3C intron 7.
The breakpoints of the duplication identified in subject
four were found to differ from those identified in the other
case subjects. The duplications are considered functionally
equivalent as their protein products are predicted to be
identical, differing at a single intronic nucleotide.
These results are consistent with tandem duplication
without inversion, described as NC_000001.11(GRCh38):
1456616_1524663dup (subjects 1–3 and 5) and
NC_000001.11(GRCh38):1456890_1524937dup (subject
4). The duplications are predicted to maintain the copy-
number of ATAD3A and ATAD3C, duplicate ATAD3B, and
create a fusion gene, ATAD3A-C, composed of ATAD3A
(Uniprot: Q9NVI7-2, residues 1–405) and ATAD3C (Uni-
prot: Q5T2N8-1, residues 231–411) (Figures 1B and 1C).274 The American Journal of Human Genetics 106, 272–279, FebruarWe performedmultiple complementary in silico analyses
to characterize the effect of the duplication. Multiple
sequence alignment of ATAD3A (NC_000001.11
(GRCh38):1512151–1534687) and ATAD3C (NC_000001.11
(GRCh38):1449689–1470158) showed the genes have an
overall sequence identity of approximately 56%. The du-
plications occur at a 673 bp region with near-complete
sequence identity between ATAD3A and ATAD3C
(Figure 1A). In silico splicing analysis of ATAD3A-C showed
that the splice sites are maintained (Figure S3). Pairwise
alignment of ATAD3A (GenBank: NM_001170535.2;
Q9NVI7-2) and ATAD3A-C (Uniprot: Q9NVI7-2, residues
1–405, and Uniprot: Q5T2N8-1, residues 231–411)
primary amino acid sequences showed that they are
of identical length and differ at 29 residues (Figure S4).
Seven of the variants (p.Val450Ile, p.Asn454Cys,
p.Gln455His, p.Asp465Ala, p.Arg466Cys, p.Asn468Asp,
and p.Glu469Val) lie within the ATPase domain (residues
348–474; Pfam: PF00004) (Figure 1D, underline; Figure 1E),
while the remaining22arepresent outside of a known func-
tional domain (p.Glu482Ala, p.Phe489Leu, p.Asp490Asn,
p.Lys491Glu, p.Gln502Arg, p.Ser516Leu, p.Val518Ile,
p.Gly527Cys, p.Glu529Lys, and p.Glu545Lys) or within a
region of predicted intrinsic disorder (p.Thr556Ala,
p.Arg557Cys, p.Ala561Phe, p.Lys568Met, p.Cys570Arg,
p.Ala574Gly, p.Gly576Arg, p.Arg579Pro, p.Gly580Glu,
p.Pro583Gln, p.Ser584Pro, and p.Pro585Ser). DeepLoc
(v1.0) was used to predict the subcellular localization ofy 6, 2020
Figure 2. Elevated ATAD3 and Free
Cholesterol Levels in Fibroblasts Harboring
the ATAD3 Gene Cluster Duplication
(A) Level of ATAD3 in fibroblast of subject 1
compared to control subjects (Fiji ImageJ
densitometric analysis). The data are the
mean of n ¼ 6 independent experiments us-
ing three different control cell lines. Error
bars show 1 standard deviation (**p < 0.01;
Welch’s t test).
(B) A representative ATAD3 immunoblot
using a pan-specific antibody in fibroblasts.
Levels of GAPDH were used as indicators of
protein loading. The increased signal of the
upper band [B] is consistent with the dupli-
cation of ATAD3B. ATAD3A isoform 2 and
the predicted ATAD3A-C fusion protein
are of identical size; hence, the increased
signal of the lower band [A] is consistent
with the fusion gene being expressed and
stable.
(C) Chart showing mean filipin signal of
cells quantified by ImageJ. Subject 1: fibro-
blasts of an individual with the ATAD3
gene cluster duplication; Deletion: fibro-
blasts of an individual with a biallelic
ATAD3 gene cluster deletion (see Desai
et al.2 for details); U18: U18666A is an inhib-
itor of cholesterol trafficking; Filipin is a
fluorescent marker, which binds specifically
to unesterified cholesterol. Data are the re-
sults of 8 independent experiments for subject 1 and control subject(s) and n¼ 6 for the ‘‘deletion.’’ Error bars show 1 standard deviation
(***p < 0.001; **p% 0.01; one-way ANOVA).
(D) Representative images of filipin-stained cells. Scale bar 10 mm.ATAD3A and ATAD3A-C. The tool was able to correctly pre-
dict that ATAD3A is transported into the mitochondrial
membrane. There was no change in this prediction for
ATAD3A-C. Together, these analyses indicate that the
fusion transcript is likely to be correctly transcribed and
translated and maintain the signals necessary for native
subcellular localization.We nextmodeled the composition
of ATAD3 hexamers using a binomial distribution based on
two copies of ATAD3A and one copy of ATAD3A-C. It is pre-
dicted that 8.8% of ATAD3 hexamers would be comprised
solely of wild-type ATAD3Amonomers, while 91.2%would
contain at least one copy of the ATAD3A-C fusion protein
(Figure S5).
To experimentally assess the predictions of the in silico
analyses we amplified a 1.8 kb product by reverse tran-
scription PCR on RNA extracted from fibroblasts (subject
4), using a primer pair specific to ATAD3A and ATAD3C.
Sanger sequencing of this product showed a sequence
identical to the predicted ATAD3A-C transcript
(Figure S6). We found that the 50 region of the ATAD3A-C
fusion transcript corresponds to that of ATAD3A, splicing
isoform two. Western blotting showed that fibroblasts
(subject 1) harboring the duplication had higher expres-
sion of ATAD3, compared to controls (Figures 2A and
2B). The upper of the two bands is where ATAD3Bmigrates
and so the increased signal is attributed to the additional
copy of ATAD3B. As ATAD3A is not fully duplicated, the
increased signal of the lower band suggests that theThe AmericaATAD3A-C protein product is expressed and stable.
ATAD3 is an established mitochondrial protein,7 and anti-
body labeling of ATAD3 in fibroblasts of subject 1 revealed
a distribution similar to control cells and to the mitochon-
drial outer membrane protein TOMM20 (Figure S7). There-
fore, both the duplicated ATAD3B and the ATAD3A-C
fusion gene protein product appear to be targeted to the
mitochondria.
Variants in bor, an ATAD3A homolog in Drosophila mela-
nogaster, are associated with a reduction in the number
of mitochondria and mitochondrial structural abnormal-
ities1 and bi-allelic ATAD3 cluster deletions have been
shown to cause mitochondrial structural abnormalities
and impaired cholesterol metabolism in human fibro-
blasts.2 Therefore, we assessed mitochondrial morphology
and cholesterol levels in our cellular models. In subject
1-derived fibroblasts, free-unesterified cholesterol assessed
by filipin staining was significantly higher than control
subjects and was similar to cells with pronounced ATAD3
deficiency caused by bi-allelic ATAD3 cluster deletions2
(Figures 2C and 2D). Many fibroblasts (subject 1) showed
aggregations of mitochondria, and swollen and rounded
organelles (Figure 3A; circled). Nevertheless, cells with an
extensive and interconnected mitochondrial network
were also apparent (Figure 3A). Immuno-staining for
DNA indicated that the swollen mitochondria contained
accumulations of mtDNA (Figure 3B; arrows). These fea-
tures are similar to those associated with ATAD3 clustern Journal of Human Genetics 106, 272–279, February 6, 2020 275
Figure 3. Abnormal Mitochondrial Morphology andmtDNAOr-
ganization in Cells with an ATAD3 Gene Cluster Duplication
(A) Confocal images showing the mitochondria of control cell
lines (C2) and fibroblasts from subject 1 (S1) labeled with an anti-
body to the outer mitochondrial membrane protein TOMM20
(red). Proportion of cells with clumped mitochondria for subject 1
versus 2 control subjects (n ¼ 2 independent experiments, R50
cells per cell line, per experiment).
(B) Fibroblast cells from control subject (C1) and subject 1 (S1)
labeled with an antibody against TOMM20 (red), a DNA antibody
(green), and DAPI (blue); arrows indicate mtDNA aggregation.
Scale bars 10 mm. Error bars show 1 standard deviation.deletions;2 we therefore infer that ATAD3A-C is dysfunc-
tional and disrupts mitochondrial morphology and
mtDNA organization and causes abnormalities in cellular
cholesterol metabolism.
In addition to creating the ATAD3A-C fusion protein,
the duplication creates an additional copy of ATAD3B. To
determine whether this may have contributed to the sub-
jects’ phenotype, exome sequence data from all individ-
uals in the Deciphering Developmental Disorders (DDD)
cohort (n ¼ 32,369) were evaluated for the presence of du-
plications affecting the ATAD3 cluster. Excluding subject 5,
who was identified in this cohort, 61 individuals were
identified with likely monoallelic duplications intersecting
the ATAD3 cluster (size range of 67 kb–1.53 Mb), of which
48 affected only the ATAD3 cluster. All duplications were
found to fully encompass ATAD3B but did not intersect276 The American Journal of Human Genetics 106, 272–279, FebruarATAD3A. Duplications were carried either by unaffected
parents or probands whose clinical features were inconsis-
tent with a probable metabolic disorder, were above the
age of 1 year at their last clinical assessment, and were alive
at the point of recruitment. Confirmation testing was not
undertaken for the apparently benign duplications, and
the precise breakpoints have not been determined. Never-
theless, the presence of multiple ATAD3B duplications in
this study cohort suggests that the duplication of ATAD3B
and increased ATAD3B gene dosage alone is not causative
of this severe phenotype, but rather the NAHR-derived re-
combinant ATAD3A-C gene and novel protein product
generated by the de novo mutational event.
We have identified two de novo duplications within the
ATAD3 cluster in five unrelated individuals whose clinical
presentation suggested a metabolic disorder. ATAD3 gene
defects were recently recognized as a cause of human dis-
ease,1–3 accounting for a growing number of phenotypes
and cases. Dominant-negative ATAD3A missense variants
have been reported in individuals affected with hypotonia,
optic atrophy, axonal neuropathy, hypertrophic cardiomy-
opathy, and hereditary spastic paraplegia.1,3 Bi-allelic
ATAD3 cluster deletions result in a more severe phenotype
with pontocerebellar hypoplasia2,14,15 and death in the
majority of case subjects within the first week of life similar
to bi-allelic ATAD3A deletions.1 These case subjects with a
monoallelic ATAD3 gene cluster duplication extend the ge-
notype spectrum of ATAD3-related disorders.
The phenotype of the neonates with ATAD3 duplica-
tions shows overlap with the previously reported cases
associated with pathogenic variation at this locus noting
corneal clouding, cardiomyopathy, hypotonia, white mat-
ter changes, seizures, fetal akinesia, and contractures. All
subjects with duplication died within 6 weeks of life.
Although four neonates had low Apgar scores and required
intensive clinical management from birth, subject 4 was
born prematurely (33þ3 weeks), achieved high Apgar
scores, had a less severe perinatal course, and presented
3 weeks later with severe lactic acidosis (Table 1 and Sup-
plemental Note). The subjects did not present with
obvious signs of mitochondrial distress, and this study
highlights the importance of considering mitochondrial
genes even in atypical cases, such as these.
The ATAD3A-C fusion protein is uniquely associated
with the severe neonatal phenotype and therefore is likely
causal. It is expressed and stable (Figures 2A, 2B, and S6)
and has the correct subcellular localization (Figure S7).
The fusion protein differs from ATAD3A at 29 amino acid
residues within the C-terminal region, including a highly
conserved residue within the ATPase domain, p.Arg466Cys
(Figure 1D; arrow and Figure 1E). The equivalent residue is
conserved in all multimeric AAA-domain containing
ATPases and functions as an arginine finger, a trans-acting
residue that binds to the g-phosphate of ATP in the
neighboring monomer.16 Multiple recurrent missense
variants have been reported at the equivalent arginine
finger residue, Arg499, in SPAST (Figure 4) and causey 6, 2020
Figure 4. Protein Modeling of ATAD3 Hexamer and 3D Align-
ment against SPAST ATPase Domain
(A) Hexameric structure of ATAD3A ATPase domain (amino acids
348–474), modeled in SwissModel using PDB: 6f0x (H. sapiens,
TRIP13) as a template. A single monomer is highlighted in violet.
(B) Single ATAD3A monomer (violet) aligned to H. sapiens SPAST
ATPase domain (blue).
(C) The ATAD3A arginine finger, Arg466 (yellow) which is
changed to a cysteine in the ATAD3A-C fusion gene, is overlaid
with the SPAST arginine finger (Arg499; orange).autosomal-dominant hereditary spastic paraplegia (SPG4
[MIM: 182601]).17,18 These variants have been shown to
result in the complete loss of SPASTATPase activity,19 lead-
ing to disease through a dominant-negative mechanism.
We suggest that the ATAD3 duplications described here
act through the same mechanism: through incorporation
of a non-functional monomer derived from the novel
fusion protein into more than 90% of ATAD3 hexamers
(Figure S5).
Our data suggest that the generation of the fusion pro-
tein causes this lethal neurological disorder through
disruption of mitochondrial and cholesterol metabolism
(Figures 2C, 2D, and 3). This reinforces the links between
ATAD3, cholesterol, and mtDNA metabolism. Consid-
ering the majority of the cholesterol in mitochondrial
membranes co-purifies with mtDNA,20 and increasing
or decreasing cholesterol availability markedly alters
mtDNA organization,2 then cholesterol dyshomeostasis
evidently disrupts mtDNA metabolism. ATAD3 has links
to cholesterol metabolism through partner proteins,The AmericaTSPO, CYP11A1, and SPTLC.6,8 ATAD3 also co-purifies
with the mitochondrial protein synthesis machinery,
mtDNA, and mitochondrial cholesterol,7,8,20 and there
is evidence that the mitochondrial nucleoprotein
complexes are interlinked.21,22 Hence perturbed choles-
terol-containing micro-domains could be the common
factor linking all the features associated with ATAD3
deficiency.
Copy number variants (CNVs) pose a practical chal-
lenge in genomic analysis, in both their detection and
interpretation. Determining how to analyze and inter-
pret rare CNVs which intersect common benign CNVs
is not trivial. The high frequency of benign duplications
seen in the ATAD3 region coupled with high sequence
homology of the three genes means that pathogenic
duplications could potentially be missed. This study
highlights the importance of systematic CNV analysis,
particularly of genomic intervals prone to instability,
where a clinical presentation is consistent with a mono-
genic disorder.
The high frequency at which this specific ATAD3 dupli-
cationwas identified within this cohort suggests that for all
clinical suspicions of severe neonatal disorder of unknown
origin, negative for known mitochondrial variants and
mitochondrial nuclear genome panels, the ATAD3 locus
should be carefully evaluated for single nucleotide, copy-
number, and structural variants.Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
1016/j.ajhg.2020.01.007.Acknowledgments
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